A global modeling study estimates that exposure to two widely used plastic additives, DEHP and DiNP, contributed to roughly 3.85 million preterm births and approximately 74,000 newborn deaths worldwide in a single year. The research, which draws on biomarker data from approximately 200 countries and territories, represents the most extensive attempt yet to quantify how phthalates in everyday consumer products affect pregnancy outcomes on a planetary scale. Its findings arrive as U.S. regulators continue to weigh the risks of these chemicals under existing law, raising hard questions about the gap between accumulating evidence and the pace of policy action.
Nearly 4 Million Preterm Births Tied to Two Chemicals
The study, published in eClinicalMedicine, a journal in The Lancet Group, modeled 2018 global exposure levels for two phthalates that are among the most common plasticizers in consumer goods. DEHP, used to soften PVC plastics in medical devices, food packaging, and building materials, was linked to an estimated 1.97 million preterm births and roughly 74,000 newborn deaths. DiNP, a replacement chemical that manufacturers have increasingly adopted as DEHP faces restrictions, was linked to an additional 1.88 million preterm births. Together, the two chemicals account for a staggering burden of preventable harm concentrated in the earliest and most vulnerable days of life.
The researchers built their exposure estimates using urinary biomarker surveys collected across approximately 200 countries and territories, then applied dose-response relationships drawn from prior epidemiological work. Financial costs associated with the modeled newborn deaths ranged from millions to hundreds of billions of dollars depending on the phthalate and region, according to a press release accompanying the study. That economic framing matters because it translates an abstract chemical-exposure problem into terms that budget offices and insurers can act on, potentially influencing how governments prioritize regulatory reviews and prevention efforts.
U.S. Cohort Data Strengthens the Case
The global estimates did not emerge in a vacuum. They build on a large body of U.S. epidemiological evidence that has been accumulating for years. A pooled analysis funded by the National Institutes of Health examined 6,045 pregnancies across 16 U.S. cohorts, with deliveries spanning 1983 to 2018. That analysis found higher odds of preterm birth among women with elevated urinary concentrations of several phthalate metabolites, and it modeled how many early deliveries could theoretically be prevented if exposures were reduced.
A related study published in The Lancet Planetary Health applied those U.S. dose-response findings to estimate attributable preterm births and associated economic costs for the United States alone in 2018. That earlier work served as a methodological blueprint for the new global analysis, extending the same analytical framework from one country to the world. The consistency between the U.S.-specific and global findings strengthens the overall case: different research teams, using overlapping but distinct datasets, arrive at the same directional conclusion that phthalate exposure during pregnancy shortens gestation and increases infant mortality risk.
The studies also highlight the importance of long-running birth cohorts and interdisciplinary research teams. Investigators with expertise in environmental epidemiology, toxicology, and biostatistics (many of whom appear in the National Institute of Environmental Health Sciences’ directory of research scientists) have spent decades building the evidence base that now underpins these global estimates. Their work illustrates how painstaking cohort follow-up, combined with biomarker analysis, can clarify health risks that would otherwise remain invisible.
What Phthalates Are and Why Exposure Is So Widespread
Phthalates are a family of synthetic chemicals added to plastics to make them flexible and durable. They appear in vinyl flooring, food containers, personal care products, and medical tubing. Because they are not chemically bonded to the plastic matrix, they leach into air, dust, food, and water over time. Virtually every person tested in biomonitoring studies shows detectable levels of phthalate metabolites in urine, which means exposure is near-universal rather than limited to occupational settings.
For pregnant women, that ubiquity is the core problem. Phthalates cross the placental barrier and have been shown in animal and human studies to disrupt endocrine signaling, interfere with progesterone pathways, and trigger inflammatory responses in uterine tissue. Each of those mechanisms can shorten gestation. The challenge for regulators is that no single product delivers a dangerous dose on its own; the risk comes from cumulative, low-level exposure across dozens of sources every day. That makes traditional chemical-by-chemical risk assessment a poor fit for the real-world exposure pattern.
Public health agencies have responded in part by emphasizing worker and community education. The National Institute of Environmental Health Sciences supports training programs through its Worker Training Program, which focuses on chemical hazards and prevention strategies. While these initiatives are not limited to phthalates, they reflect a broader shift toward empowering people who handle or encounter industrial chemicals to recognize exposure pathways and advocate for safer conditions.
EPA’s DiNP Review Highlights Regulatory Gaps
The regulatory picture for phthalates in the United States illustrates the tension between new health evidence and existing legal frameworks. The EPA finalized a risk evaluation for DiNP under the Toxic Substances Control Act, determining that the chemical presents an unreasonable risk to human health only for certain worker exposures involving spray-applied products. For consumers and the general population, the agency found no identified risk contributing to unreasonable risk.
That conclusion sits uneasily alongside the new global data. The EPA evaluation focused on DiNP in isolation and assessed hazard endpoints including developmental toxicity, liver damage, and cancer at higher exposure levels. But the agency’s risk framework did not account for cumulative phthalate exposure from multiple sources, which is exactly the exposure pattern the epidemiological studies flag as harmful to pregnancies. The manufacturer-requested evaluation was submitted through the American Chemistry Council’s industry-led process, and critics argue that this narrow scope left out vulnerable populations such as pregnant people and infants who may be exposed to mixtures of phthalates rather than a single compound.
The contrast underscores a structural challenge: TSCA risk evaluations are designed around individual chemicals and specific uses, whereas real-world exposures are diffuse, overlapping, and often involve chemicals that may act on similar biological pathways. As a result, regulators can conclude that each chemical, considered alone, does not pose an “unreasonable risk” to the general population, even while population-level studies detect significant health burdens attributable to the group as a whole.
Signals Beyond Pregnancy
Concerns about phthalates also intersect with broader questions about how early-life chemical exposures shape long-term health. Environmental health researchers increasingly examine links between prenatal exposures and developmental outcomes, including neurodevelopmental conditions. Seminars such as the NIEHS-hosted autism research series and international meetings like the IMACS conference on environmental modeling and children’s health reflect a growing scientific focus on how mixtures of pollutants may influence brain development as well as birth timing.
While the new phthalate modeling study centers on preterm birth and neonatal mortality, its authors note that preterm infants face elevated risks of lifelong health challenges, including respiratory problems, learning difficulties, and chronic disease. That means the harms quantified for 2018 likely represent only the beginning of a much longer cascade of medical and social costs. For policymakers, the implication is that reducing phthalate exposure could yield benefits that extend far beyond the delivery room.
What Comes Next
The study’s authors call for stronger international coordination on phthalate regulation, arguing that current patchwork policies leave many populations unprotected. Some countries restrict certain phthalates in toys or food contact materials, while others have yet to act. Even where bans exist, replacement chemicals such as DiNP may carry similar risks, raising the specter of “regrettable substitution” in which one hazardous plasticizer is simply swapped for another with less-studied but still concerning properties.
In the United States, the findings are likely to intensify debate over how the EPA and other agencies evaluate cumulative exposures and protect pregnant people and infants. Advocates have urged regulators to treat phthalates as a class rather than one by one, to incorporate up-to-date epidemiological evidence into risk assessments, and to prioritize safer materials in medical devices and food packaging. Industry groups, meanwhile, emphasize compliance with existing regulations and point to the benefits of flexible plastics in healthcare and consumer products.
For now, individual families have limited tools to reduce exposure beyond basic steps such as minimizing microwaving in plastic, choosing fragrance-free personal care products, and supporting policies that phase out high-concern plasticizers. The new modeling work does not offer immediate solutions, but it does sharpen the stakes: millions of early births and tens of thousands of newborn deaths each year may be tied to a small set of chemicals embedded in the global plastic economy. Whether regulators move quickly enough to close that gap between evidence and action remains an open, urgent question.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
